Nalaganje...
Tofacitinib for the treatment of tumor necrosis factor-α inhibitor refractory esophageal Crohn’s disease: a case report
BACKGROUND: Esophageal Crohn’s disease is reported as a rare manifestation, although its prevalence may be underestimated because upper endoscopies are not routinely performed in asymptomatic adults. Tofacitinib, an oral janus kinase inhibitor, is a new biologic that has shown promise in the treatme...
Shranjeno v:
| izdano v: | J Med Case Rep |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5034573/ https://ncbi.nlm.nih.gov/pubmed/27663846 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13256-016-1036-y |
| Oznake: |
Označite
Brez oznak, prvi označite!
|